Bixiye
Upcoming pharmacy program policy activity effective Dec. 1, 2020
Natiijooyinka Raadinta
Soo bandhiga 2321 - 2330 ee natiijooyinka 3701
Bixiye
P81-20 eviCore Healthcare Specialty Utilization Management (UM) Program - Cardiology and Radiology Clinical Guideline Updates for Fully Insured Commercial and Medicare Advantage Subscribers
Taariikhda uu dhaqangalayo Barnaamijka: Nov 02, 2020
Bixiye
QP50-19 Pharmacy Benefit Exclusion for Intramuscular Route of Administration Medications
Taariikhda wax ku ool ah ee barnaamijka: Jun 12, 2019
Bixiye
QP105-20 Update: EquiClaim to Perform Focused and Limited Hospital Bill Validation (HBV) Services
Taariikhda uu dhaqangalayo barnaamijka: Okt 28, 2020
Bixiye
P85-20 Updated Minnesota Health Care Programs and Minnesota Senior Health Options (MSHO) Prior Authorization and Medical Policy Requirements
Taariikhda uu dhaqangalayo Barnaamijka: Nov 02, 2020
Bixiye
P80-20 New Medical, Medical Drug and Behavioral Health Policy Management Updates—Effective January 4, 2021
Taariikhda uu dhaqangalayo Barnaamijka: Nov 02, 2020
Bixiye
P82-20 eviCore Healthcare Specialty Utilization Management (UM) Program – Medical Oncology Drug Prior Authorization Updates for Fully Insured Commercial and Medicare Advantage Subscribers
Taariikhda uu dhaqangalayo Barnaamijka: Nov 02, 2020
Bixiye
QP100-20 MHCP Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Hemophilia Factor IX PA with QL
Taariikhda uu dhaqangalayo barnaamijka: Okt 14, 2020
Bixiye
QP95-20 Commercial Pharmacy Benefit Exclusion for Jelmyto®
Taariikhda uu dhaqangalayo barnaamijka: Okt 14, 2020
Bixiye
QP94-20 Commercial Pharmacy Benefit Exclusion for Condylox®, Lyumjev™, Veregen® and Zilxi™
Taariikhda uu dhaqangalayo barnaamijka: Okt 14, 2020